Skip to main content
EWTX logo

EWTX · Edgewise Therapeutics, Inc.

Track EWTX — free
$39.91 -1.27 (-3.07%) At close · Nov 20
Market Cap
$4.37B
Shares
109.48M
Volume · Nov 20 1.19M Avg daily vol (3M) 1.53M

Price & Indicators

 

Key stats

Close
$39.91
Fri 20 Nov
Open
$40.81
Fri 20 Nov
Average volume, 30 days
1.6M
shares a session
Short interest
12.7M
11.6% of shares · 9.6 days to cover
Day range
$39.71$41.41
Open $40.81 Close $39.91
52-week closing range
$20.94$48.74
Close $39.91 18.1% under the high
Short volume, last session
42%
Last earnings
May 13, 2024
Latest filing
10-Q · Nov 4
Price history
Mar 2021 to Nov 2026

Latest documents

2026
Nov 10
Investor event
FDA accepts tolerability-based dosing to 150 milligrams

EWTX said the FDA accepted a late-stage design allowing physicians to titrate 7500 by tolerability toward a 150 milligrams target dose. Separate obstructive and non-obstructive HCM trials will use peak VO2 as the primary endpoint and include an adaptive design.

6 source passages
# Conference Transcript - EWTX 2026-11-10 And what we put out... Last Thursday was with our conversations with the FDA, we requested not to have any monitoring of the patients to get to the target dose, which is 150 milligrams. And what we asked was allow the PI or allow the physician to determine what is the appropriate dose for each individual patient. That was accepted by the agency. Do you think that's long enough for 7500 to show its full effect? The agency preferred and told us directly that they would like to see statistical significance in both the non-obstructive and an isolated obstructive HCM population. So what that means is, well, if I have to hit STAT-SIG on both, I might as well run them as separate trials under essentially an umbrella protocol. The agency also preferred peak VO2 as a primary endpoint and allow things like KCCQ. Other functional measures and things like VEV and over VECO2 to be measured as secondary endpoints and looked at separately. So the other fourth important point in that press release was that we have engineered into the protocol an adaptive design. Open the document at this passage
Nov 4
Current report 8-K
Sevasemten sale drives profit; EDG-7500 Phase 3 advances

Edgewise Therapeutics, Inc. reported $1,166.2 million in third-quarter net income, including a $1.348 billion gain from the sevasemten sale, and expects to initiate the EDG-7500 Phase 3 trial by year-end 2026.

Financial results
4 source passages
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights. Gain on sevasemten sale was $1.348 billion for the third quarter of 2026 and reflects the completion of the sale of the sevasemten program and muscular dystrophy business to Servier in July 2026. Net income and net income per share were $1,166.2 million, or $10.71 per basic share and $9.65 per diluted share, for the third quarter of 2026 Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Sevasemten pivotal study misses endpoints

Edgewise reported that Servier announced on November 3, 2026 that sevasemten’s pivotal GRAND CANYON study in Becker muscular dystrophy missed its primary and secondary endpoints; milestone payments remain contingent on regulatory and commercial outcomes controlled by Servier.

Net income $1.17B Diluted EPS $9.65
Read from the MD&A section
2 source passages
The following discussion of the financial condition and results of operations of Edgewise Therapeutics, Inc. should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q (Quarterly Report), and the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K (Annual Report), filed with the Securities and Exchange Commission, on February 26, 2026. On November 3, 2026, Servier announced that the pivotal GRAND CANYON study of sevasemten in Becker muscular dystrophy did not meet its primary or secondary endpoints. Servier is conducting further analysis of the study results and relevant prior clinical data. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$1.01B
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
4.9
Trailing earnings · reciprocal yield 20.5%
FCF yield
-4.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$68.68M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.6%
Year over year · more shares
Price change (1Y)
+79.3%
Trailing year
Short interest
11.6%
Latest settlement · 9.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +7%
above
Price vs 50-day avg −3%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 68%
mid-range
Momentum
relative strength
Very Strong
1-month return +2%
trailing
6-month return +7%
trailing
YTD return +61%
this year
Relative strength +16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $41 › 200d $37 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +45 funds added
Insider flow Distributing
Net -$201.8K over 90 days · 100% sells
Short interest Rising
11.60% of shares out · ▲ +8.0% MoM · 9.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
254 holders — near 3-yr high, broad support
Squeeze score 72
high risk · 0–100
Fundamentals
Fair
EPS growth −12%
Y/Y
Free cash flow $-144.1M
Valuation P/E 4.9
below peers
Balance sheet $61.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 73%
annualized · 1-yr
Max drawdown −25%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+7% Bullish
Price vs 50-day avg
−3% Neutral
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
68% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $41 › 200d $37 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +45 funds added
Insider flow Distributing
Net -$201.8K over 90 days · 100% sells
Short interest Rising
11.60% of shares out · ▲ +8.0% MoM · 9.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
254 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $21 Now $40 · 68% Range high $49
vs 200-day avg +7% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EWTX
Edgewise Therapeutics, Inc.
this stock
$4.37B +60.8% — 4.9 11.6%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
254
% held
114.2%
Net QoQ
+5.9M sh
Top holder
ORBIMED ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
237
View
Short & Settlement
Short Interest Rising
Shares short
12.7M
Days to cover
9.6d
Change
+944.4K sh
View
Short Volume
Short vol %
42%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
226
Value
$9.9K
As of
Sep 9, 2026
View
Off-Exchange
Off-exchange %
46.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$201.8K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-167.8M
EPS diluted
$-1.63
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
17

EWTX said the FDA accepted a late-stage design allowing physicians to titrate 7500 by tolerability toward a 150 milligrams target dose. Separate obstructive and non-obstructive HCM trials will use peak VO2 as the primary endpoint and include an adaptive design.

View
Proposed Sales
Value
$39.2K
Shares
854
Filed
Nov 16, 2026
View
Exempt Offerings
Offering
$95.0M
Filed
Dec 10, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Edgewise Therapeutics to Particip…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
EWTX -13.1% +1.5% +7.1% +2.6% +60.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -4.6% +10.7% +16.3% +11.3% +59.7%
Key facts CIK 1710072 CUSIP 28036F105 13F (30d) 260 filings 237 filers Visit website Investor relations